Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
Rattachement africain : us, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: receptor agonist for acute treatment of migraine. Because SS symptoms are heterogeneous, diagnosis can be challenging, and potential cases observed with lasmiditan treatment led to questions about SS pathophysiology. Here, we provide an overview of the potential risk of SS based on experience with lasmiditan. Methods: = 88) were analyzed for symptomatology consistent with SS. Post-marketing surveillance data from lasmiditan's US launch date (January 2020) until data cut-off (April 2021) were also examined. Established Sternbach and Hunter diagnostic criteria were used for formal determination of SS. Results: Of 6,004 lasmiditan-treated clinical trial patients, 15 reported ≥1 treatment-emergent adverse event consistent with signs and symptom(s) of SS. After review, one case met Sternbach and Hunter criteria, two cases potentially met Sternbach criteria, and three cases reported as SS had limited/no information to determine if either criterion was met. During post-marketing surveillance (approximately 13,400 lasmiditan prescriptions), 17 cases with symptom complexes consistent with SS were reported; 3/17 cases had adequate case descriptions to apply predefined criteria. Of these, two met Sternbach and Hunter criteria, and one met Sternbach criteria. Conclusion: Awareness of clinical symptomatology and diagnostic criteria of SS can help clinicians with recognition of rare instances of SS that may occur with lasmiditan. Clinical trial registration: NCT03670810, NCT00384774, NCT00883051, NCT02565186.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
- Date Crossref
- 27/10/2023
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Neurology Center of Southern California pays non établi dans la noticeÉtablissement de santé
-
Dartmouth–Hitchcock Medical Center pays non établi dans la noticeÉtablissement de santé
-
Eli Lilly (United Kingdom) pays non établi dans la noticeEntreprise
-
Eli Lilly (United States) pays non établi dans la noticeEntreprise
-
Geisel School of Medicine at Dartmouth pays non établi dans la noticeUniversité ou école supérieure
-
Eli Lilly and Company pays non établi dans la noticeEntreprise
Neurology Center of Southern California, Dartmouth–Hitchcock Medical Center et Eli Lilly (United Kingdom), avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.